- Home
- ASAN vs IMVT Comparison
ASAN vs IMVT Comparison
Compare ASAN & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASAN
- IMVT
- Stock Information
- Founded
- ASAN 2008
- IMVT 2018
- Country
- ASAN United States
- IMVT United States
- Employees
- ASAN N/A
- IMVT N/A
- Industry
- ASAN Retail: Computer Software & Peripheral Equipment
- IMVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASAN Technology
- IMVT Health Care
- Exchange
- ASAN Nasdaq
- IMVT Nasdaq
- Market Cap
- ASAN 3.1B
- IMVT 2.7B
- IPO Year
- ASAN 2020
- IMVT N/A
- Fundamental
- Price
- ASAN $13.97
- IMVT $18.12
- Analyst Decision
- ASAN Hold
- IMVT Buy
- Analyst Count
- ASAN 16
- IMVT 10
- Target Price
- ASAN $16.70
- IMVT $40.14
- AVG Volume (30 Days)
- ASAN 3.6M
- IMVT 1.3M
- Earning Date
- ASAN 09-02-2025
- IMVT 08-05-2025
- Dividend Yield
- ASAN N/A
- IMVT N/A
- EPS Growth
- ASAN N/A
- IMVT N/A
- EPS
- ASAN N/A
- IMVT N/A
- Revenue
- ASAN $738,695,000.00
- IMVT N/A
- Revenue This Year
- ASAN $10.27
- IMVT N/A
- Revenue Next Year
- ASAN $8.90
- IMVT N/A
- P/E Ratio
- ASAN N/A
- IMVT N/A
- Revenue Growth
- ASAN 9.84
- IMVT N/A
- 52 Week Low
- ASAN $11.05
- IMVT $12.72
- 52 Week High
- ASAN $27.77
- IMVT $34.47
- Technical
- Relative Strength Index (RSI)
- ASAN 46.67
- IMVT 68.50
- Support Level
- ASAN $13.18
- IMVT $16.88
- Resistance Level
- ASAN $14.95
- IMVT $17.10
- Average True Range (ATR)
- ASAN 0.49
- IMVT 0.71
- MACD
- ASAN 0.24
- IMVT 0.16
- Stochastic Oscillator
- ASAN 64.36
- IMVT 99.65
About ASAN Asana Inc.
Asana is a provider of collaborative work management software delivered via a cloud-based SaaS model. The firm's solution offers scalable, dynamic tools to improve the efficiency of project and process management across countless use cases, including marketing programs, managing IT approvals, and performance management. Asana's offering supports workflow management across teams, provides real time visibility into projects, and reporting and automation capabilities. The firm generates revenue via software subscriptions on a per seat basis.
About IMVT Immunovant Inc.
Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.